211 related articles for article (PubMed ID: 17593991)
1. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
Tarighi B; Kurum T; Demir M; Azcan SN
Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
[TBL] [Abstract][Full Text] [Related]
2. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
[TBL] [Abstract][Full Text] [Related]
3. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
Vyssoulis GP; Marinakis AG; Aznaouridis KA; Karpanou EA; Arapogianni AN; Cokkinos DV; Stefanadis CI
Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977
[TBL] [Abstract][Full Text] [Related]
4. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
von Fallois J; Faülhaber HD
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Merchant N; Searles CD; Pandian A; Rahman ST; Ferdinand KC; Umpierrez GE; Khan BV
J Clin Hypertens (Greenwich); 2009 Dec; 11(12):720-5. PubMed ID: 20021529
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
Rosei EA; Rizzoni D; Comini S; Boari G;
Blood Press Suppl; 2003 May; 1():30-5. PubMed ID: 12800985
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
Himmelmann A; Hedner T; Snoeck E; Lundgren B; Hedner J
Eur J Clin Pharmacol; 1996; 51(3-4):259-64. PubMed ID: 9010695
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
Agabiti Rosei E; Rizzoni D
Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
[TBL] [Abstract][Full Text] [Related]
11. [Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].
Gromnatskiĭ NI; Dius'mikeeva NB
Kardiologiia; 2002; 42(10):27-30. PubMed ID: 12494053
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol: third-generation beta-blockade.
de Boer RA; Voors AA; van Veldhuisen DJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study.
Vaz-de-Melo RO; Giollo-Júnior LT; Martinelli DD; Moreno-Júnior H; Mota-Gomes MA; Cipullo JP; Yugar-Toledo JC; Vilela-Martin JF
Sao Paulo Med J; 2014; 132(5):290-6. PubMed ID: 25054966
[TBL] [Abstract][Full Text] [Related]
14. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study.
Schmidt AC; Graf C; Brixius K; Scholze J
Clin Drug Investig; 2007; 27(12):841-9. PubMed ID: 18020542
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: in the treatment of hypertension in the US.
Baldwin CM; Keam SJ
Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.
Fogari R; Zoppi A; Lazzari P; Mugellini A; Lusardi P; Preti P; Van Nueten L; Vertommen C
J Hum Hypertens; 1997 Nov; 11(11):753-7. PubMed ID: 9416986
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
Makris TK; Stavroulakis GA; Krespi PG; Hatzizacharias AN; Triposkiadis FK; Tsoukala CG; Votteas VV; Kyriakidis MK
Am J Hypertens; 2000 Jul; 13(7):783-8. PubMed ID: 10933570
[TBL] [Abstract][Full Text] [Related]
19. [Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study].
von Fallois J; Faulhaber HD
Praxis (Bern 1994); 2001 Mar; 90(11):435-41. PubMed ID: 11293936
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
Giles TD; Khan BV; Lato J; Brener L; Ma Y; Lukic T
J Clin Hypertens (Greenwich); 2013 Sep; 15(9):687-93. PubMed ID: 24034663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
